Greenland Mines Ltd. (GRML) 12-Month Stock Forecast & Price Target Cone

$4.58 -10.89% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.48

Greenland Mines Ltd. (GRML) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $70.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GRML Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GRML stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Greenland Mines Ltd. (NASDAQ: GRML) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.58 (-10.89% 1D, market cap $70.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GRML ranks #780 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GRML compare to CGTX and CRDF in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GRML carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CGTX (Cognition Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and CRDF (Cardiff Oncology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $70.9M). Among the 5-stock peer group, GRML leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GRML?
▼

Per GRML's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001907223), Greenland Mines Ltd. generated $0 in revenue, -$10.6M in net income, and -$5.9M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.48 (-2.15%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (6)Whales (5)SEC (10)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.8% Base Target
$39 Bull$4 Base$3 Bear
📬 FREE GRML RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRML)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY GRML SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (25% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 39 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$5.17+16.1% Next Q
Q2 (-2Q)
37
Grade E$6.00-3.7% Next Q
Q3 (-1Q)
35
Grade E$5.78-20.8% Next Q
Current
32
Grade E$4.58-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GRML Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GRML currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.60) and Max Pain ($4.81) forces dealer call-delta covering toward $38.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GRML• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GRML Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your GRML Position Size: $10,000

Shares at $4.58: 2183.4 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $3.15
$6,878
$-3,122 (-31.2%)
12M Consensus BaseTarget $4.04
$8,821
$-1,179 (-11.8%)
12M Bull Case BreakoutTarget $38.85
$84,825
+$74,825 (+748.3%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$474%A
Goldman SachsSector Coverage LeadUNDERPERFORM$3769%B
JP MorganUS Large-Cap ResearchSELL$458%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRML)

  • ✓Walkthrough of GRML's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GRML // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -81.00%📐 HORIZONTAL RANGE
2026-10-30O $5.00H $5.00L $4.35C $4.58VOL 1.36M
RES: $18.74SUP: $-0.50SMA50: $6.60SMA200: $13.74
$29.23$22.07$14.91$7.76$0.60RES $18.74SUP $-0.50$4.582026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GRML Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GRML today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GRML. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GRML today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRML)

Health Care Rank #780 of 1016 ⚔️ CGTX vs GRML Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GRML vs. CGTX, CRDF, NMRA, CSBR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Greenland Mines Ltd. (GRML) ranks #780 by composite RQD confidence (32/100, grade E) and #706 by equity capitalization ($70.3M). Within this direct 5-issuer industry benchmark cohort, GRML leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with GRML at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GRML ACTIVE
Greenland Mines Ltd.
E 32/100 — — -35.0% -10.89% $70.3M Benchmark Subject
CGTX
Cognition Therapeutics Inc.
D- 43/100 — — -35.0% -5.57% $70.3M /cgtx-vs-grml →
CRDF
Cardiff Oncology Inc.
D- 41/100 — — -35.0% -2.46% $70.9M /crdf-vs-grml →
NMRA
Neumora Therapeutics Inc.
D- 42/100 — — -35.0% -5.43% $73.0M /nmra-vs-grml →
CSBR
Champions Oncology Inc.
E 22/100 — 48.0% -26.9% 0.00% $66.9M /csbr-vs-grml →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001907223

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Greenland Mines Ltd. (GRML) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$10.6M, operating cash flow of -$5.9M, and free cash flow of -$5.9M (-99.9% YoY). On the balance sheet, GRML closed FY2025 with $9.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$10.6M -$5.9M -$5.9M $9.6M —
FY2024 (FY) 2024-12-31 $0 -$6.2M -$2.9M -$2.9M $2.5M —
FY2023 (FY) 2023-12-31 $0 -$707.5K -$446.9K -$446.9K — —

3. GRML Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GRML stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Greenland Mines Ltd. (NASDAQ: GRML) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.58 (-10.89% 1D, market cap $70.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GRML ranks #780 in composite RQD confidence.

How does GRML compare to CGTX and CRDF in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GRML carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CGTX (Cognition Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and CRDF (Cardiff Oncology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $70.9M). Among the 5-stock peer group, GRML leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GRML?

Per GRML's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001907223), Greenland Mines Ltd. generated $0 in revenue, -$10.6M in net income, and -$5.9M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GRML trading relative to its 50-day, 200-day, and 52-week technical levels?

GRML last traded at $4.58 (-10.89% on volume of 1,359,728 shares), positioning the stock -30.61% below its 50-day simple moving average ($6.60) and -66.67% below its 200-day simple moving average ($13.74). Across its 52-week range of $2.82 to $37.00, GRML sits at the 5.1% percentile with a 14-day RSI of 39.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.01 to $5.15).

GRML Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is GRML's 12-month stock price target?

Greenland Mines Ltd. (GRML) carries a 12-month consensus base price target of $4.04 (-11.8% from $4.58), with a bull-case target of $38.85 and a bear-case floor of $3.15.

Is GRML stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates GRML E (Strong Sell — SELL) with an RQD Confidence score of 32/100.

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GRML — Greenland Mines Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:45:38Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating assigns GRML a score of 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). The five pillars are:

  • Fundamental Cash Engine: 6 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and FCF yield of -8.37%. For a prospective investor, the company is currently destroying capital and not generating free cash flow relative to its market value, which removes the most durable source of intrinsic support.
  • Whale 13F Flow: 5 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is low, indicating limited evidence of sustained institutional conviction in the source data.
  • Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. It is the lowest pillar score, meaning the signal from insider and congressional activity does not support the thesis.
  • Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. Market-level exposure is neutral by beta, but the score indicates weak alignment with the current macro regime.
  • Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. The Piotroski reading is weak, and the score reflects forensic caution despite a moderate Altman Z.

Taken together, the pillars point to a stock where the cash engine, insider signal, and forensic quality all score in the weak range. Upside would depend on a reversal in cash generation, which the current data does not show. Valuation tradeoffs are difficult to assess because P/E and EV/EBITDA are not available in source data, and the 52-week range of $2.82 to $37 illustrates very high volatility relative to the current $4.58 price.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-7.1M$-10.6MN/A$-5.9M$7.2MN/A
FY 2024$0.0M$-5.5M$-6.2MN/A$-2.9M$0.1MN/A
FY 2023$0.0M$-0.6M$-0.7MN/A$-0.4MN/AN/A

Per the SEC financials, reported losses widened across the three periods, with net income moving from $-0.7M to $-10.6M and free cash flow from $-0.4M to $-5.9M. Gross, operating, and net margins are each 0% per the market data, consistent with zero reported revenue. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 2/9. Debt/Equity is 0.5 per the Roarable RQD rating, while debt in the SEC financials is Not available in source data for each period; the balance-sheet posture therefore rests on cash of $7.2M at FY 2025 against the company's negative cash flows.

Open Questions

  • What products, customers, or development programs generate or are expected to generate revenue, given zero reported revenue in each period?
  • What are the debt obligations behind the Debt/Equity of 0.5, since debt is not reported in the SEC financials?
  • How much of the $59 million raised is already reflected in the FY 2025 cash of $7.2M, and what is the dilution impact on share count?
  • Is the $20M buyback funded from existing cash, and how does it reconcile with negative free cash flow of $-5.9M?
  • What is the reason for the 52-week range of $2.82 to $37, and what drove the current $4.58 price?

GRML Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Greenland Mines Ltd. (GRML) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GRML Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GRML Bull vs. Bear Conversation Board — What's Your Call at $4.58?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GRML 🐻 67% BEARISH CONVICTION
1. Pick Your Side on GRML:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.03 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GRML (E • RQD 32/100) a Buy at $4.58?

Welcome to the GRML (Greenland Mines Ltd.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.48 (-24.0%)
Spot @ $4.58

Pump the brakes on GRML — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GRML, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Greenland Mines Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $5.82 (+27.1%)
Spot @ $4.58

GRML cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GRML, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $4.58 (52-wk range $2.82 - $37.00), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%